<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016898</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00048136</org_study_id>
    <nct_id>NCT02016898</nct_id>
  </id_info>
  <brief_title>The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device</brief_title>
  <official_title>The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary focus of this study is to assess intraocular pressure and complication rates
      between patients who receive mitomycin-C using a sponge versus no-sponge.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 17, 2017</completion_date>
  <primary_completion_date type="Actual">January 17, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complication Rates</measure>
    <time_frame>post-operative day 1 to month 6</time_frame>
    <description>To assess complication rates between patients who receive mitomycin-C using a sponge versus irrigation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Intraocular Pressure</measure>
    <time_frame>post-operative day 1 to month 6</time_frame>
    <description>To assess final intraocular pressure lowering between patients who receive mitomycin-C using a sponge versus irrigation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Sponge placement of Mitomycin-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Irrigation placement of Mitomycin-C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placement of the sponge</intervention_name>
    <arm_group_label>Sponge placement of Mitomycin-C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitomycin-C</intervention_name>
    <arm_group_label>Sponge placement of Mitomycin-C</arm_group_label>
    <arm_group_label>Irrigation placement of Mitomycin-C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women aged 18 years and older at screening.

          2. Diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, phakic or
             pseudophakic, with visual field or optic disc changes characteristic of glaucoma.

          3. Suitable candidate for trabeculectomy with Ex-PRESS glaucoma filtration device with
             MMC in the superonasal quadrant in the study eye which the physician deems as
             medically necessary.

          4. Capable and willing to provide consent

        Exclusion Criteria:

          1. Unable or unwilling to provide consent

          2. Any previous ocular surgeries in the study eye preventing placement of the
             trabeculectomy with Ex-PRESS glaucoma filtration device with mitomycin-C in the
             superonasal quadrant

          3. Any previous glaucoma drainage devices in the study eye

          4. Any abnormality other than glaucoma in the study eye that could affect applanation
             tonometry.

          5. Presence or history of any abnormality or disorder that could interfere with the study
             procedure or prevent the successful completion of the study.

          6. Presence or history of uveitis within 10 years or any other ocular infection or
             inflammation within 14 days before day 1.

          7. Any significant unstable cardiovascular, hepatic, renal, respiratory,
             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or
             psychiatric disease.

          8. Known Pregnancy or Breastfeeding

             Physical and Laboratory Findings

          9. Conjunctival scarring precluding a superonasal implantation location.

         10. Vitreous in the anterior chamber.

         11. Abnormality preventing reliable applanation tonometry in the study eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon Herndon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <results_first_submitted>January 11, 2018</results_first_submitted>
  <results_first_submitted_qc>January 11, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 9, 2018</results_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary open angle glaucoma</keyword>
  <keyword>trabeculectomy</keyword>
  <keyword>mitomycin-C</keyword>
  <keyword>express mini-shunt</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two subjects were retroactively removed due to not satisfying the inclusion/exclusion criteria. An additional three subjects had uncertain group allocation due to clerical errors.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sponge Placement of Mitomycin-C</title>
          <description>Randomization stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Placement of the sponge
Mitomycin-C</description>
        </group>
        <group group_id="P2">
          <title>Irrigation Placement of Mitomycin-C</title>
          <description>Randomization stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Irrigation placement
Mitomycin-C</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sponge Placement of Mitomycin-C</title>
          <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Placement of the sponge
Mitomycin-C</description>
        </group>
        <group group_id="B2">
          <title>Irrigation Placement of Mitomycin-C</title>
          <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Irrigation placement
Mitomycin-C</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9.6"/>
                    <measurement group_id="B2" value="73.1" spread="8.3"/>
                    <measurement group_id="B3" value="70.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complication Rates</title>
        <description>To assess complication rates between patients who receive mitomycin-C using a sponge versus irrigation</description>
        <time_frame>post-operative day 1 to month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sponge Placement of Mitomycin-C</title>
            <description>Randomization stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Placement of the sponge
Mitomycin-C</description>
          </group>
          <group group_id="O2">
            <title>Irrigation Placement of MMC</title>
            <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Irrigation placement
Mitomycin-C</description>
          </group>
        </group_list>
        <measure>
          <title>Complication Rates</title>
          <description>To assess complication rates between patients who receive mitomycin-C using a sponge versus irrigation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Intraocular Pressure</title>
        <description>To assess final intraocular pressure lowering between patients who receive mitomycin-C using a sponge versus irrigation</description>
        <time_frame>post-operative day 1 to month 6</time_frame>
        <population>Five participants in each group were not included due to being lost to follow-up or deceased.</population>
        <group_list>
          <group group_id="O1">
            <title>Sponge Placement of Mitomycin-C</title>
            <description>Randomization stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Placement of the sponge
Mitomycin-C</description>
          </group>
          <group group_id="O2">
            <title>Irrigation Placement of MMC</title>
            <description>Randomization will be stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Irrigation placement
Mitomycin-C</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Intraocular Pressure</title>
          <description>To assess final intraocular pressure lowering between patients who receive mitomycin-C using a sponge versus irrigation</description>
          <population>Five participants in each group were not included due to being lost to follow-up or deceased.</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.4" spread="1.6"/>
                    <measurement group_id="O2" value="-8.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.539</p_value>
            <method>t-test, 1 sided</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.01</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sponge Placement of Mitomycin-C</title>
          <description>Randomization stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Placement of the sponge
Mitomycin-C</description>
        </group>
        <group group_id="E2">
          <title>Irrigation Placement of Mitomycin-C</title>
          <description>Randomization stratified by age (age ≥65 or age &lt; 65), baseline IOP (IOP ≥ 28 mmHg or IOP &lt; 28 mmHg), and concurrent cataract surgery.
Irrigation placement
Mitomycin-C</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic blebs</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Shallowing of anterior chamber</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hypotony</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Choroidal effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Suprachoroidal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Hyphema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Wound leak</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Quist, MD</name_or_title>
      <organization>Duke University Health System</organization>
      <phone>718-490-7657</phone>
      <email>michael.quist@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

